<DOC>
	<DOC>NCT02581124</DOC>
	<brief_summary>Study to evaluate the effect of lapatinib, a breast cancer resistance protein (BCRP) inhibitor, on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety and tolerability of JTZ-951 when administered alone and one hour after the administration of lapatinib.</brief_summary>
	<brief_title>Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Subjects with end stage renal disease on hemodialysis Postdialysis body weight &gt;45.0 kg BMI between 18.0 and 40.0 kg/m2 (inclusive) Subjects with positive test results for HBsAg (hepatitis B surface antigen), HCV antibody or HIV antibody Subjects with known history of liver failure or liver surgery Subjects with a history or current clinically significant chronic or acute blood loss</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>JTZ-951</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>